Should I buy or sell MoonLake Immunotherapeutics stock right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MoonLake Immunotherapeutics in the last year. There are currently 3 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" MLTX shares. View MLTX analyst ratings or view top-rated stocks .

What is MoonLake Immunotherapeutics' stock price target for 2024?

12 brokers have issued 12 month target prices for MoonLake Immunotherapeutics' shares. Their MLTX share price targets range from $56.00 to $100.00. On average, they predict the company's stock price to reach $74.46 in the next year. This suggests a possible upside of 76.5% from the stock's current price. View analysts price targets for MLTX or view top-rated stocks among Wall Street analysts .

How have MLTX shares performed in 2024?

MoonLake Immunotherapeutics' stock was trading at $60.39 at the beginning of 2024. Since then, MLTX shares have decreased by 30.1% and is now trading at $42.19. View the best growth stocks for 2024 here .

When is MoonLake Immunotherapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our MLTX earnings forecast .

How were MoonLake Immunotherapeutics' earnings last quarter?

MoonLake Immunotherapeutics (NASDAQ:MLTX) announced its earnings results on Thursday, February, 29th. The company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.11.

What ETFs hold MoonLake Immunotherapeutics' stock?

ETFs with the largest weight of MoonLake Immunotherapeutics (NASDAQ:MLTX) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO) , Harbor Health Care ETF (MEDI) , AdvisorShares Dorsey Wright Micro-Cap ETF (DWMC) and First Trust IPOX Europe Equity Opportunities ETF (FPXE) . Goldman Sachs Future Health Care Equity ETF (GDOC) .

How do I buy shares of MoonLake Immunotherapeutics?

Shares of MLTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:MLTX

MoonLake Immunotherapeutics (MLTX) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free MLTX Stock Alerts

$42.19

-0.06 (-0.14%)

(As of 04/19/2024 ET)

Compare

Today's Range: $40.68
▼
$42.80
50-Day Range: $42.19
▼
$63.86
52-Week Range: $19.80
▼
$64.98

Volume: 527,548 shs
Average Volume: 465,669 shs
Market Capitalization: $2.70 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $74.46

Get MoonLake Immunotherapeutics alerts:

MoonLake Immunotherapeutics MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.75 Rating Score
Upside/Downside: 76.5% Upside
$74.46 Price Target
Short Interest: Bearish
16.21% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.26
Based on 2 Articles This Week
Insider Trading: Selling Shares
$9.49 M Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($1.11) to ($1.56) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.86 out of 5 stars

Medical Sector

603rd out of 911 stocks

Pharmaceutical Preparations Industry

261st out of 411 stocks

4.4

Analyst's Opinion

Consensus Rating
MoonLake Immunotherapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 9 buy ratings, 3 hold ratings, and no sell ratings.
Amount of Analyst Coverage
MoonLake Immunotherapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

0.0

Short Interest

Percentage of Shares Shorted
16.21% of the float of MoonLake Immunotherapeutics has been sold short.
Short Interest Ratio / Days to Cover
MoonLake Immunotherapeutics has a short interest ratio ("days to cover") of 15.9, which indicates bearish sentiment.
Change versus previous month
Short interest in MoonLake Immunotherapeutics has recently increased by 9.29%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
MoonLake Immunotherapeutics does not currently pay a dividend.
Dividend Growth
MoonLake Immunotherapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for MLTX.

1.3

News and Social Media Coverage

News Sentiment
MoonLake Immunotherapeutics has a news sentiment score of 0.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for MoonLake Immunotherapeutics this week, compared to 3 articles on an average week.
Search Interest
Only 6 people have searched for MLTX on MarketBeat in the last 30 days. This is a decrease of -86% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added MoonLake Immunotherapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -83% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, MoonLake Immunotherapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,490,674.00 in company stock.
Percentage Held by Insiders
15.27% of the stock of MoonLake Immunotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
93.85% of the stock of MoonLake Immunotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for MoonLake Immunotherapeutics are expected to decrease in the coming year, from ($1.11) to ($1.56) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of MoonLake Immunotherapeutics is -55.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of MoonLake Immunotherapeutics is -55.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
MoonLake Immunotherapeutics has a P/B Ratio of 5.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Paradigm Press

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.

Click here to find out that this 8,788% cryptocurrency is.

About MoonLake Immunotherapeutics Stock (NASDAQ:MLTX)

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

MLTX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

MLTX Stock News Headlines

April 13, 2024 | americanbankingnews.com

HC Wainwright Reiterates Buy Rating for MoonLake Immunotherapeutics (NASDAQ:MLTX)

April 12, 2024 | americanbankingnews.com

MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Average Recommendation of "Moderate Buy" from Brokerages

April 20, 2024 | InvestorPlace (Ad)

The #1 Crypto for 2024

5 Tiny Cryptos That Could Soar During 2024 Crypto Bull Run One of the first ever crypto millionaires who bought Bitcoin when it was trading for just $5 in 2011 is back with his next huge prediction. A newly approved government regulation is set to flood trillions of dollars into the crypto markets, leading to the FINAL crypto bull run. One of the "Kings of Crypto" has revealed five tiny cryptos that could soar over the course of 2024. Potentially resulting in gains as big as 10X, 50X, or even 100X over the next 12 months.

April 11, 2024 | markets.businessinsider.com

MoonLake Immunotherapeutics Buy Rating: Strategic Partnerships and Market Potential Fuel Optimism

April 10, 2024 | globenewswire.com

MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions

April 10, 2024 | businesswire.com

MoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint Conditions

April 10, 2024 | americanbankingnews.com

MoonLake Immunotherapeutics' (MLTX) "Buy" Rating Reaffirmed at Needham & Company LLC

April 2, 2024 | msn.com

Goldman starts MoonLake at neutral, cites lead drug potential

April 20, 2024 | InvestorPlace (Ad)

The #1 Crypto for 2024

March 25, 2024 | finance.yahoo.com

MLTX Aug 2024 80.000 call

March 12, 2024 | finance.yahoo.com

MLTX May 2024 60.000 call

March 12, 2024 | finance.yahoo.com

MLTX Apr 2024 40.000 put

March 11, 2024 | marketwatch.com

MoonLake Immunotherapeutics Shares Rise Premarket After Pipeline Update

March 11, 2024 | msn.com

Why Is Inflammatory Disease-Focused MoonLake Immunotherapeutics Stock Trading Higher Today?

March 11, 2024 | realmoney.thestreet.com

MoonLake price target raised to $100 from $75 at H.C. Wainwright

March 10, 2024 | globenewswire.com

MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day

March 4, 2024 | markets.businessinsider.com

Buy Rating Affirmed for MoonLake Immunotherapeutics Amid Promising Clinical and Regulatory Advances

March 4, 2024 | globenewswire.com

MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024

March 1, 2024 | finance.yahoo.com

Insider Sell: CEO Santos da Silva Jorge Sells 123,615 Shares of MoonLake Immunotherapeutics (MLTX)

February 29, 2024 | globenewswire.com

MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10

February 28, 2024 | markets.businessinsider.com

MoonLake Immunotherapeutics: A Promising Buy on Streamlined Clinical Progress and Regulatory Synergy

February 26, 2024 | globenewswire.com

MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody® sonelokimab (SLK) in Hidradenitis Suppurativa (HS)

February 25, 2024 | seekingalpha.com

MoonLake Immunotherapeutics: Novel Technology, But Still In Phase 3

February 22, 2024 | benzinga.com

MoonLake Stock (NASDAQ:MLTX) Dividends: History, Yield and Dates

February 22, 2024 | benzinga.com

MoonLake Stock (NASDAQ:MLTX), Short Interest Report

February 21, 2024 | finance.yahoo.com

Insider Sell: CEO Santos da Silva Jorge Sells 60,000 Shares of MoonLake Immunotherapeutics

February 17, 2024 | finance.yahoo.com

MLTX Mar 2024 80.000 call

See More Headlines

Receive MLTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MoonLake Immunotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/29/2024
Today: 4/20/2024
Next Earnings (Estimated): 5/10/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:MLTX
CUSIP: N/A
CIK: 1821586
Web: www.moonlaketx.com
Phone: 41-41-510-8022
Fax: N/A
Employees: 50
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $74.46
High Stock Price Target: $100.00
Low Stock Price Target: $56.00
Potential Upside/Downside: +76.5%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.75
Research Coverage: 12 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.76)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-36,010,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -9.22%
Return on Assets: -9.00%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 51.59
Quick Ratio: 51.59

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $8.15 per share
Price / Book: 5.18

Miscellaneous

Outstanding Shares: 63,890,000
Free Float: 54,131,000
Market Cap: $2.70 billion
Optionable: Optionable
Beta: 1.20

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

Dr. Jorge Santos da Silva (Age 46)
Co-Founder, CEO & Director
Comp: $1.11M
Dr. Kristian Reich (Age 58)
Co-Founder & Chief Scientific Officer
Comp: $1.2M
Mr. Matthias Bodenstedt (Age 36)
Chief Financial Officer
Comp: $588.25k
Mr. Oliver Daltrop
Chief Technical Officer
Nicolas Mosimann
General Counsel
Luciana Marques
Director of HR, People & Culture
Ms. Nuala Brennan
Chief Clinical Development Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

MLTX Stock Analysis - Frequently Asked Questions

Should I buy or sell MoonLake Immunotherapeutics stock right now?: 12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MoonLake Immunotherapeutics in the last year. There are currently 3 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" MLTX shares.
View MLTX analyst ratings or view top-rated stocks.
What is MoonLake Immunotherapeutics' stock price target for 2024?: 12 brokers have issued 12 month target prices for MoonLake Immunotherapeutics' shares. Their MLTX share price targets range from $56.00 to $100.00. On average, they predict the company's stock price to reach $74.46 in the next year. This suggests a possible upside of 76.5% from the stock's current price.
View analysts price targets for MLTX or view top-rated stocks among Wall Street analysts.
How have MLTX shares performed in 2024?: MoonLake Immunotherapeutics' stock was trading at $60.39 at the beginning of 2024. Since then, MLTX shares have decreased by 30.1% and is now trading at $42.19.
View the best growth stocks for 2024 here.
When is MoonLake Immunotherapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our MLTX earnings forecast.

How were MoonLake Immunotherapeutics' earnings last quarter?: MoonLake Immunotherapeutics (NASDAQ:MLTX) announced its earnings results on Thursday, February, 29th. The company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.11.
What ETFs hold MoonLake Immunotherapeutics' stock?: ETFs with the largest weight of MoonLake Immunotherapeutics (NASDAQ:MLTX) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO), Harbor Health Care ETF (MEDI), AdvisorShares Dorsey Wright Micro-Cap ETF (DWMC) and First Trust IPOX Europe Equity Opportunities ETF (FPXE).Goldman Sachs Future Health Care Equity ETF (GDOC).
How do I buy shares of MoonLake Immunotherapeutics?: Shares of MLTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MLTX) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial